Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Start buying in tariff-hit sectors but diversify & stagger it over the next 6 months : Sunil Subramaniam
16/04/2025
Positive Breakout : These 9 stocks cross above their 200 DMAs
16/04/2025
FPIs raise stake in these 10 stocks, witness up to 175% returns despite broader selloff
16/04/2025
Australian politicians took $147,000 of match tickets while weighing sports betting ban
16/04/2025
Trump picks a Hunter Biden whistleblower to temporarily lead the IRS
16/04/2025
Q4 results today : Wipro, Waree Renewables among 10 companies to announce earnings on Wednesday
16/04/2025
